Trial Profile
A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Linaclotide (Primary) ; Linaclotide (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Allergan; Ironwood Pharmaceuticals
- 01 May 2023 Results (n=2350) of post hoc analysis pooled from studies (NCT02559206, NCT03573908, NCT00948818, and NCT00938717) published in the American Journal of Gastroenterology
- 26 Oct 2022 Results(n=2073) of post hoc analysis pooled from studies(NCT02559206,NCT00948818, NCT00938717 and NCT03573908) assessing the Safety and Efficacy of Linaclotide in Patients With Irritable Bowel Syndrome and Constipation presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
- 01 Feb 2021 Results published in the American Journal of Gastroenterology